# Rani Therapeutics Holdings Inc. (RANI)

Source: https://www.quantisnow.com/company/RANI
Generated: 2026-11-11T15:17:14.205Z

- Ticker: RANI
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001856725
- Website: ranitherapeutics.com

## About

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

## Latest RANI news and filings

- 2026-11-09 22:22 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-rani-therapeutics-holdings-inc-6782087)
- 2026-11-09 22:00 UTC [SEC Form 8-K] [Rani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/rani-therapeutics-holdings-inc-filed-sec-form-8-k-results-of-6781951)
- 2026-11-09 21:05 UTC [Earnings] [Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update](https://www.quantisnow.com/insight/rani-therapeutics-reports-third-quarter-2026-financial-results-provides-corporate-6781172)
- 2026-10-13 20:05 UTC [Conference Announcement] [Rani Therapeutics to Participate in the Chardan Healthcare Conference](https://www.quantisnow.com/insight/rani-therapeutics-to-participate-in-the-chardan-healthcare-conference-6744931)
- 2026-10-05 12:00 UTC [Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)](https://www.quantisnow.com/insight/rani-therapeutics-announces-acceptance-into-us-fdas-emerging-technology-program-6735952)
- 2026-09-29 20:42 UTC [SEC Form 4] [Chief Executive Officer Imran Talat covered exercise/tax liability with 7,928 shares, decreasing direct ownership by 2% to 461,808 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-executive-officer-imran-talat-covered-exercisetax-liability-with-7928-6729420)
- 2026-09-29 20:36 UTC [SEC Form 4] [Chief Technical Officer Javadi Alireza covered exercise/tax liability with 309 shares, decreasing direct ownership by 3% to 9,071 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-technical-officer-javadi-alireza-covered-exercisetax-liability-with-309-6729394)
- 2026-09-08 12:00 UTC [Conference Announcement] [Rani Therapeutics to Participate in Upcoming September Conferences](https://www.quantisnow.com/insight/rani-therapeutics-to-participate-in-upcoming-september-conferences-6707512)
- 2026-08-18 12:29 UTC [Analyst Coverage Initiated] [Chardan Capital Markets initiated coverage on Rani Therapeutics with a new price target](https://www.quantisnow.com/insight/chardan-capital-markets-initiated-coverage-on-rani-therapeutics-with-a-6685982)
- 2026-08-14 20:46 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-rani-therapeutics-holdings-6683459)
- 2026-08-13 20:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-rani-therapeutics-holdings-inc-6680674)
- 2026-08-13 20:11 UTC [SEC Form 8-K] [Rani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/rani-therapeutics-holdings-inc-filed-sec-form-8-k-results-of-6680500)
- 2026-08-13 20:05 UTC [Public Offering] [Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update](https://www.quantisnow.com/insight/rani-therapeutics-reports-second-quarter-2026-financial-results-provides-corporate-6680234)
- 2026-08-10 12:00 UTC [Conference Announcement] [Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://www.quantisnow.com/insight/rani-therapeutics-to-participate-in-the-canaccord-genuity-46th-annual-6672784)
- 2026-08-05 00:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Gilson Michelle](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gilson-michelle-6663492)
- 2026-08-05 00:48 UTC [SEC Form 3] [SEC Form 3 filed by new insider Gilson Michelle](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-gilson-michelle-6663490)
- 2026-08-04 12:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-rani-therapeutics-holdings-inc-6661226)
- 2026-08-04 12:00 UTC [Leadership Update] [Rani Therapeutics Appoints Michelle Gilson to Board of Directors](https://www.quantisnow.com/insight/rani-therapeutics-appoints-michelle-gilson-to-board-of-directors-6661170)
- 2026-07-23 20:10 UTC [Insider Buy] [Director Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)](https://www.quantisnow.com/insight/director-imran-mir-a-bought-24840-worth-of-shares-36000-6647060)
- 2026-07-21 23:24 UTC [SEC Form 4] [Chief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-technical-officer-javadi-alireza-sold-301-worth-of-shares-6644306)
- 2026-07-21 22:29 UTC [Insider Buy] [Chief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-imran-talat-bought-25193-worth-of-shares-6644288)
- 2026-07-21 22:25 UTC [SEC Form 4] [Chief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-executive-officer-imran-talat-sold-11300-worth-of-shares-6644283)
- 2026-07-21 20:51 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Maestas Nicholas](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-maestas-nicholas-6644098)
- 2026-07-20 20:05 UTC [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-6642398)
- 2026-07-15 21:09 UTC [SEC Form S-8] [SEC Form S-8 filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-rani-therapeutics-holdings-inc-6638589)
- 2026-07-15 12:00 UTC [Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing](https://www.quantisnow.com/insight/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-6637605)
- 2026-07-09 20:05 UTC [Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates](https://www.quantisnow.com/insight/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-to-6632944)
- 2026-07-08 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Maestas Nicholas](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-maestas-nicholas-6631528)
- 2026-06-29 12:00 UTC [Leadership Update] [Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer](https://www.quantisnow.com/insight/rani-therapeutics-appoints-nicholas-maestas-as-chief-financial-officer-6618292)
- 2026-06-05 22:20 UTC [SEC Form 4] [SEC Form 4 filed by Chief Business Officer Mckinley Kate](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-business-officer-mckinley-kate-6592113)
- 2026-06-05 22:17 UTC [SEC Form 4] [SEC Form 4 filed by Chief Technical Officer Javadi Alireza](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-technical-officer-javadi-alireza-6592104)
- 2026-06-05 22:14 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Imran Talat](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-imran-talat-6592100)
- 2026-06-01 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Bassan Abraham](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bassan-abraham-6581694)
- 2026-06-01 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Rometty Lisa Ann](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rometty-lisa-ann-6581683)
- 2026-06-01 20:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Imran Mir A](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-imran-mir-a-6581677)
- 2026-06-01 20:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Butel Jean Luc](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-butel-jean-luc-6581664)
- 2026-06-01 20:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Bailey Vasudev Jaiprakash](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bailey-vasudev-jaiprakash-6581659)
- 2026-06-01 20:08 UTC [SEC Form 4] [SEC Form 4 filed by Director Ausiello Dennis A](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ausiello-dennis-a-6581658)
- 2026-05-28 21:47 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-rani-therapeutics-holdings-6577819)
- 2026-05-27 00:41 UTC [SEC Form 8-K] [SEC Form 8-K filed by Rani Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-rani-therapeutics-holdings-inc-6573600)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RANI
- Earnings history: https://www.quantisnow.com/earnings/RANI
- Dividend history: https://www.quantisnow.com/dividends/RANI
- Insider transactions: https://www.quantisnow.com/insiders/RANI
- Options chain: https://www.quantisnow.com/options/RANI
- SEC 8-K filings only: https://www.quantisnow.com/company/RANI/8-k
- RSS and alerts for RANI: https://www.quantisnow.com/docs/rss-feeds.md